Phase 3 N=610 Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
Dry Eye Syndrome
Primary: Ocular Discomfort Scale — -0.6; -0.6 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=452 Study of SkQ1 as Treatment for Dry-eye Syndrome
Dry Eye Syndrome
Primary: Central Corneal Staining Change From Baseline — -0.28; -0.3; -0.2 score on a scale
Phase 3 N=430 Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
Open Angle Glaucoma · Ocular Hypertension
Primary: Mean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry — 15.39; 15.56; 15.64; 15.25 mmHg — p=<0.05
Phase 3 N=406 Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Type 2 Diabetes Mellitus
Primary: Change in Glycated Hemoglobin (HbA1c) (%) — -0.46; -1.14; -1.48; -1.59 HbA1c (%)
Phase 3 N=424 A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Multiple Sclerosis · Walking Impairment
Primary: Number of Patients With Adverse Events — 122; 116; 86 Participants
Phase 3 N=404 Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain
Degenerative Disc Disease
Primary: Overall Treatment Success: Bayesian Estimated Response Rate — 0.267; 0.335; 0.313 BE proportion of participants
Phase 3 N=366 An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With Remission Based on Composite Score at Week 52 — 6; 38; 11; 33 Participants — p=<0.001
Phase 3 N=163 Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
Familial Hypercholesterolemia
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 36; 69; 7; 25 Participants
Phase 3 N=809 Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
Breast Cancer · Breast Neoplasms · HER2-positive Breast Cancer
Primary: Proportion of Subjects in Each Treatment Arm Who Achieve Pathologic Complete Response (pCR) — 172; 185; 164; 153 participants
Phase 3 N=419 Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
Esophageal Cancer
Primary: Overall Survival — 10.9; 8.4 months
Phase 3 N=326 A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-Verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-Treat Population — 6.7; 42.8…
Phase 3 N=158 Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer
Stage II Prostate Cancer · Stage IIA Prostate Cancer · Stage IIB Prostate Cancer
Primary: Knowledge Assessed by Prostate Cancer Treatment Questionnaire — 0.69; 0.65; 0.58; 0.56 percentage of items correct
Phase 3 N=61 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Prostate Adenocarcinoma · PSA Failure · Recurrent Prostate Carcinoma
Primary: Confirmation of Prostate Cancer Recurrence by 68Ga-PSMA-11 PET/CT — 46; 15 Participants
Phase 3 N=59 Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children
Migraine
Primary: Change in Pain Score After Analgesic Administration (Faces Pain Scale - Revised (FPS-R) — 4.2; 4.4 units on a scale
Phase 3 N=2,414 Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
Influenza · Human · Virus Diseases
Primary: Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HAI)…